NASDAQ: PROK PROKIDNEY CORP. 10-K

ProKidney advances to late-stage with FDA accelerated approval pathway confirmed for rilparencel

Filed March 18, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 17, 2025 · ~2 min read

5 material changes detected in this filing.

Create a free account to read the full summary — it takes 30 seconds.

Partner

Trade PROK commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.